FIND AN ATTORNEY FIND AN OFFICE

We follow industry news and trends so you can stay ahead of the game. Subscribe to receive emails regarding policies and findings that impact you and your business.

Already a subscriber and want to update your preferences? Click here.

Subscribe

BACK TO EVENTS

SEP 21 2020

Key Business and IP Considerations for Furthering Drug Repurposing Programs

Sep 21 2020

1:15 PM

Edward John Allera, co-chair of the firm's FDA group, and Matthew Fedowitz, shareholder in the firm's Intellectual Property section, will present Key Business and IP Considerations for Furthering Drug Repurposing Programs for the 9th Annual Repositioning, Repurposing and Rescue Conference.

The presentation will cover the following:

Increasing the value of your 505(b)(2)
Dealing with CMS actions that increase the value of independent 505(b)(2)s
Monitoring FDA and Congress for the impact of user fees on 505(b)(2)s
Assessing the impact of Executive Orders on 505(b)2()s